Malaria control and elimination are threatened by the emergence and spread of resistance to artemisinin-based combination therapies (ACTs). Experimental evidence suggests that when an artemisinin (ART)-sensitive (K13 wild-type) Plasmodium falciparum strain is exposed to ART derivatives such as dihydroartemisinin (DHA), a small population of the early ring-stage parasites can survive drug treatment by entering cell cycle arrest or dormancy. After drug removal, these parasites can resume growth. Dormancy has been hypothesized to be an adaptive physiological mechanism that has been linked to recrudescence of parasites after monotherapy with ART and, possibly contributes to ART resistance. Here, we evaluate the in vitro drug sensitivity profile of normally-developing P. falciparum ring stages and DHA-pretreated dormant rings (DP-rings) using a panel of antimalarial drugs, including the Plasmodium phosphatidylinositol-4-OH kinase (PI4K)-specific inhibitor KDU691. We report that while KDU691 shows no activity against rings, it is highly inhibitory against DP-rings; a drug effect opposite to that of ART. Moreover, we provide evidence that KDU691 also kills DP-rings of P. falciparum ART-resistant strains expressing mutant K13.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443816 | PMC |
| http://dx.doi.org/10.1038/s41598-017-02440-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ethiopian Plasmodium vivax hypnozoites formation dynamics and their susceptibility to reference antimalarial drugs.
BMC Infect Dis
June 2023
Université des Sciences, des Techniques et des Technologies de Bamako (USTTB), Malaria Research and Training Center (MRTC), Bamako, Mali.
Article Synopsis
- Malaria elimination is hindered by Plasmodium vivax due to its persistent hypnozoite form in the liver, which leads to relapsing infections and complicates transmission interruption, especially in Duffy-positive individuals traditionally found outside Africa.
- Recent studies using molecular techniques have identified P. vivax in Duffy-negative people in various African countries, highlighting a gap in research focus primarily on falciparum malaria and limited lab infrastructure for studying P. vivax.
- Field transmission of Ethiopian P. vivax was established for research in Mali, revealing that while tafenoquine effectively inhibits hypnozoite and schizont forms, atovaquone and KDU691 have no effect on hypnozoites but are
Comparative Susceptibility of Plasmodium ovale and Plasmodium falciparum Field Isolates to Reference and Lead Candidate Antimalarial Drugs in Ghana.
Microbiol Spectr
June 2023
Malaria Research and Training Centre (MRTC), Faculty of Pharmacy, Université des Sciences, des Techniques et des Technologies de Bamako (USTTB), Point G, Bamako, Mali.
Article Synopsis
- Malaria treatments have reduced the prevalence of Plasmodium falciparum, but other species, particularly those in sub-Saharan Africa, are becoming more common and lack effective treatment data.
- A study evaluated the epidemiology and drug susceptibility of these infections over one year, finding that existing antimalarials like artesunate and lumefantrine were effective against different species, with chloroquine still inhibitory despite being withdrawn in Ghana.
- The study highlighted the need for targeted therapies against specific species that can cause relapsing malaria, emphasizing the importance of new drug classes, such as imidazolopiperazines and PI4K inhibitors, for effective treatment strategies in combating malaria in Ghana.
Plasmodium malariae and Plasmodium falciparum comparative susceptibility to antimalarial drugs in Mali.
J Antimicrob Chemother
July 2021
Malaria Research and Training Centre (MRTC), Faculty of Pharmacy, Université des Sciences, des Techniques et des Technologies de Bamako (USTTB); Point G, P.O. Box: 1805, Bamako, Mali.
Article Synopsis
- The study assesses how susceptible Plasmodium malariae is to various current and experimental antimalarial drugs.
- Results show reduced effectiveness of traditional drugs like chloroquine, lumefantrine, and artemether against P. malariae, while piperaquine and newer drugs like GNF179 and KDU691 were found to be highly effective.
- The findings suggest the need to reconsider the use of standard treatments for P. malariae infections and highlight the promising potential of newer drug candidates.
Developing Plasmodium vivax Resources for Liver Stage Study in the Peruvian Amazon Region.
ACS Infect Dis
April 2018
Division of Host-Microbe Systems and Therapeutics, Health Sciences Center for Immunology, Infection and Inflammation, Department of Pediatrics, School of Medicine , University of California, San Diego , 9500 Gilman Drive #0760 , La Jolla , California 92093-0760 , United States.
To develop new drugs and vaccines for malaria elimination, it will be necessary to discover biological interventions, including small molecules that act against Plasmodium vivax exoerythrocytic forms. However, a robust in vitro culture system for P. vivax is still lacking.
View Article and Find Full Text PDFThe Plasmodium PI(4)K inhibitor KDU691 selectively inhibits dihydroartemisinin-pretreated Plasmodium falciparum ring-stage parasites.
Sci Rep
May 2017
Novartis Institute for Tropical Diseases, 10 Biopolis Road, #05-01 Chromos, 138670, Singapore, Singapore.
Malaria control and elimination are threatened by the emergence and spread of resistance to artemisinin-based combination therapies (ACTs). Experimental evidence suggests that when an artemisinin (ART)-sensitive (K13 wild-type) Plasmodium falciparum strain is exposed to ART derivatives such as dihydroartemisinin (DHA), a small population of the early ring-stage parasites can survive drug treatment by entering cell cycle arrest or dormancy. After drug removal, these parasites can resume growth.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!